We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

158 hedge funds and large institutions have $3.61B invested in Loxo Oncology, Inc in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 48 increasing their positions, 55 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $2.74B → $3.61B (+$875M)

12% more funds holding

Funds holding: 141158 (+17)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

13% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 55

52% less call options, than puts

Call options by funds: $16.8M | Put options by funds: $34.9M

Holders
158
Holders Change
+17
Holders Change %
+12.06%
% of All Funds
3.62%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
36
Increased
48
Reduced
55
Closed
15
Calls
$16.8M
Puts
$34.9M
Net Calls
-$18M
Net Calls Change
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$500M -$16.6M -155,754 -3%
AC
2
Aisling Capital
New York
$397M
Sands Capital Management
3
Sands Capital Management
Virginia
$246M -$15.2M -142,636 -6%
Vanguard Group
4
Vanguard Group
Pennsylvania
$244M +$15M +141,244 +7%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$227M +$39.8M +373,946 +23%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$227M -$13.4M -126,215 -6%
BlackRock
7
BlackRock
New York
$209M -$2.83M -26,647 -1%
O
8
OppenheimerFunds
New York
$121M -$1.3M -12,230 -1%
State Street
9
State Street
Massachusetts
$117M -$17.4M -163,589 -14%
O
10
OrbiMed
New York
$109M -$9.91B -93,159,036 -99%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$86.5M -$84.4M -793,192 -51%
Lord, Abbett & Co
12
Lord, Abbett & Co
New Jersey
$76.9M +$12.2M +114,963 +21%
AllianceBernstein
13
AllianceBernstein
Tennessee
$64.9M -$15.7M -147,794 -21%
PC
14
Polar Capital
United Kingdom
$55.9M +$308K +2,893 +0.6%
Victory Capital Management
15
Victory Capital Management
Texas
$51.4M -$598K -5,625 -1%
DCM
16
Driehaus Capital Management
Illinois
$46.8M -$18M -168,880 -29%
BC
17
Boxer Capital
California
$46.1M +$42.5M +400,000 New
CC
18
Casdin Capital
New York
$41.5M
Ameriprise
19
Ameriprise
Minnesota
$39.6M +$28.6M +269,320 +365%
RSCM
20
Rock Springs Capital Management
Maryland
$36.5M +$691K +6,500 +2%
Norges Bank
21
Norges Bank
Norway
$34.4M +$3.89M +36,578 +14%
Northern Trust
22
Northern Trust
Illinois
$32.9M -$13K -122 -0%
Franklin Resources
23
Franklin Resources
California
$28.4M -$26.3M -247,581 -50%
EAM
24
Eventide Asset Management
Massachusetts
$26.4M -$5.96M -56,000 -20%
TCM
25
TimesSquare Capital Management
New York
$25.8M +$23.8M +223,834 New

LOXO Hedge Fund Activity: Q1 2018 in Review

158 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2018, worth a combined $3.61B — up 32% from $2.74B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 15 closed out — a net gain of 21 holders — while 48 added to existing stakes and 55 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $42.5M. The largest seller was OrbiMed, cutting an estimated $9.91B.

  • 158 institutional investors held Loxo Oncology, Inc (LOXO) as of Q1 2018, up from 141 in Q4 2017.
  • Funds reported $3.61B of Loxo Oncology, Inc stock for Q1 2018, up 32% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q1 2018 and 15 closed out, a net change of +21 holders.
  • The largest Loxo Oncology, Inc buyer in Q1 2018 was Boxer Capital, an estimated $42.5M added.
  • The largest Loxo Oncology, Inc seller in Q1 2018 was OrbiMed, an estimated $9.91B sold.

Based on aggregated 13F filings for Q1 2018.